MedTrace Logo

Electroencephalography Study Investigating the Effects of Vortioxetine in Healthy Male Subjects

NCT02072278 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2015-09-01

No results posted yet for this study

Summary

To explore a neurophysiological marker (electroencephalography) of cognitive effect of vortioxetine

Conditions

  • Healthy Men

Interventions

DRUG

Vortioxetine 10 mg

DRUG

Vortioxetine 20 mg

DRUG

Escitalopram 15 mg

DRUG

Placebo

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2014-11-30

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02072278 on ClinicalTrials.gov